Is Your Paper Ready for the New England Journal of Medicine? A Practical Submission Guide

NEJM uses the ScholarOne Manuscripts online submission system for all submissions. You'll need a structured abstract (250 words maximum), the full manuscript (2,700 words for Original Articles), a protocol and statistical analysis plan (required for all interventional trials), and any supplementary materials; a cover letter is optional. NEJM returns manuscripts that far exceed the word-count limits unread.

Here's what catches people off guard: NEJM's ICMJE compliance isn't a checkbox exercise. Every author must complete a separate financial disclosure form, submitted through CONVEY after NEJM sends each author a link during the revision process, and NEJM must receive all forms before a manuscript can be accepted. If you've got 40 co-authors on a multicenter trial, that's 40 individual forms. Start collecting them early. I've seen submissions delayed by weeks because a co-investigator in another time zone didn't fill out their form.

Clinical trials need a registration number from an acceptable registry (one that is owned by a nonprofit entity, is publicly accessible, and contains the 20 fields required by the WHO). This isn't optional and it isn't retroactive. If your trial wasn't registered before the first patient was enrolled, NEJM won't consider the manuscript, and it turns away manuscripts describing primary results of nonregistered trials before peer review.

One thing that's easy to overlook: NEJM requires a data sharing statement. You don't need to share the raw data at submission, but you need to state your plan. Will you deposit data in a repository? Make it available on request? The editors want to know your intentions upfront.

Not everything at NEJM is an Original Article. Picking the wrong article type is one common way to get a desk rejection, and it happens more often than you'd think.

Original Articles are the flagship. These are full-length research reports with a 2,700-word limit and a structured abstract. If you're reporting results from a clinical trial, a large cohort study, or a major epidemiological analysis, this is your category. The word limit is strict. Don't submit 3,800 words and hope the editors will make an exception. They won't.

Special Articles report scientific results of original research in areas such as economic policy, ethics, law, and health care delivery, with the same 2,700-word limit as Original Articles. If your work doesn't fit neatly into a clinical trial or observational study but has major implications for how medicine is practiced or delivered, this might be the right home.

Brief Reports describe a single patient, a single family, or a small series of patients, with a 1,600-word limit, a summary of up to 100 words, 3 tables and figures, and 25 references. Think of a case series with an unexpected pattern. These aren't easier to get published. The bar for significance is the same; you're just presenting less data.

Case Records of the Massachusetts General Hospital are a distinctive NEJM format, but they are not among the article types NEJM's Author Center lists for submission, so they aren't case reports you pitch.

Reviews and Editorials are usually solicited by NEJM editors, though unsolicited submissions may be considered. If you want to propose a review, send a Presubmission Inquiry first; NEJM strongly recommends one for a review that has not been solicited.

Letters to the Editor (Correspondence) are a short format. If you've got a focused comment on a recently published NEJM article, or a brief observation that doesn't warrant a full report, a letter is the right format. A letter about an NEJM article (submitted within three weeks of its publication) may not exceed 175 words, and a letter not about a specific NEJM article may not exceed 400 words.

This is where NEJM separates itself from nearly every other medical journal. NEJM says a paper moved to Revision status is sent on for statistical review, an additional review step, and that most research manuscripts it publishes undergo at least one statistical review by one of five statistical consultants before acceptance. It catches problems that clinical reviewers routinely miss.

NEJM's statistical reviewers aren't just checking whether you used the right test. They're evaluating the entire analytical framework: study design, sample size justification, randomization procedures, handling of missing data, multiplicity adjustments, and whether your conclusions actually follow from the numbers.

Common problems that trigger statistical revision requests or rejection:

Multiple primary endpoints without correction. If you tested three primary endpoints and didn't adjust for multiplicity, the statistical editor will flag it immediately. NEJM's statistical guidelines call it essential that multiplicity methods, such as a hierarchical testing procedure, be explicitly prespecified in the protocol or statistical analysis plan.

Post hoc subgroup analyses dressed up as pre-specified. Your statistical analysis plan should match what you actually did. If you added subgroup analyses after seeing the data, label them as exploratory. Trying to pass them off as planned comparisons is something the statistical editors have seen thousands of times.

Missing data handled with last observation carried forward. LOCF is outdated, and NEJM's statisticians know it. Use multiple imputation or mixed models for repeated measures, and include sensitivity analyses showing your results are stable under different missing data assumptions.

Sample size calculations that don't match enrollment. If your power calculation assumed 500 patients per arm and you enrolled 380, you need to address this. Did you adjust the analysis? Was the effect size larger than anticipated? The statistical editor will notice the discrepancy.

Non-inferiority trials with inappropriate margins. If you ran a non-inferiority trial, the choice of margin matters enormously. A margin that's too wide makes the trial uninformative. NEJM's editors have strong opinions about what constitutes a clinically meaningful margin, and they'll push back if yours doesn't hold up.

My advice: have an independent biostatistician review your manuscript before you submit. Not the statistician who ran the analysis. Someone fresh who can audit the methods section with critical eyes. It's worth the extra two weeks.

NEJM publishes timing for only two stages. Here's what it says:

NEJM says initial in-house review is typically completed in less than one week, so if you're going to be desk-rejected you will usually know quickly. That's fast enough that trying NEJM first, even with modest confidence, doesn't cost you much. A quick desk rejection followed by redirection to The Lancet or JAMA is a reasonable strategy.

Papers that reach external review have passed the first editorial screen, but NEJM publishes no acceptance rate for that stage. If you get reviewer comments back, they are useful whatever the outcome.

One thing to watch: NEJM's revision stage. NEJM says multiple iterations of peer review, statistical review, and revision will most likely occur before a manuscript is ready to be accepted, and each revision needs two versions of the manuscript, one with changes tracked or highlighted and one without. That sounds manageable until you realize you might need to rerun analyses, get updated disclosure forms, or negotiate revisions with 15 co-authors. Start working on revisions the day the decision letter arrives.

NEJM says about 5% of original research submissions achieve publication, so most submissions end in rejection. If yours does, you've got two paths.

The appeal. NEJM's published author pages describe no appeals process. An appeal should present new information the editors didn't have: new data, a factual error in the rejection rationale, or a misunderstanding of the study design. "We disagree with the decision" isn't an appeal. It's a complaint, and it won't change anything.

The redirect. This is the more productive path for most people. After an NEJM rejection, the natural next steps are The Lancet (JIF ~109, similar scope but with more global health emphasis), JAMA (JIF ~65.4, strong on evidence-based medicine), or BMJ (JIF ~55.1, stronger in UK and international contexts). For specialty-specific work, consider the top journal in your field: Circulation for cardiology, Journal of Clinical Oncology for oncology, or Annals of Internal Medicine for general medicine.

Don't just reformat and resubmit the same manuscript to the next journal. Use the rejection as diagnostic information. If NEJM desk-rejected you, it likely means the clinical significance wasn't clear enough or the study didn't address a broad enough patient population. Revise the framing before you send it elsewhere.

If you received reviewer comments before rejection, those comments are gold. Reviewers chosen by NEJM are among the best in their fields. Address their concerns in the revised manuscript even though you're submitting elsewhere. The next journal's reviewers will likely raise similar issues.

A the New England Journal of Medicine manuscript fit check at this stage can identify scope mismatches and common structural issues before you finalize your submission.

Here's a concrete checklist for the submission package:

Manuscript formatting:

• 2,700-word limit for Original Articles (introduction through conclusion or discussion, excluding the abstract, figure legends, and table notes)

• Structured abstract: Background, Methods, Results, Conclusions (250 words max)

• References: up to 40 for Original Articles, numbered consecutively as cited and double-spaced

• Tables and figures: a maximum of 5 tables and figures in total for Original Articles; extensive tables or supplementary materials go in the supplementary appendix

Compliance documents:

• Financial disclosure forms for every author (individual completion required, collected through CONVEY during revision)

• A statement of IRB or ethics committee approval, where applicable

• Informed consent statement

• Clinical trial registration number (for all interventional studies)

• CONSORT-format flow diagram, plus the relevant CONSORT checklist information, which NEJM encourages (for clinical trials)

• Statistical analysis plan (NEJM requires one for observational studies, even if it was written after the fact)

• Data sharing statement

Competing interests: NEJM posts the disclosure forms filed by all authors alongside the full text of each research article. Financial relationships, consulting fees, advisory board memberships, stock holdings, patent interests, all should be declared. If there's any relationship that could be perceived as a conflict, disclose it.

Preprints: NEJM accepts manuscripts that have been posted on a nonprofit preprint server and asks authors to notify it of any preprint related to the submission.

Before submitting, running your manuscript through a NEJM compliance, formatting, and statistical red-flag check can flag formatting gaps, missing compliance elements, and statistical red flags that would otherwise lead to an administrative return or desk rejection.

For manuscripts targeting the New England Journal of Medicine, five patterns generate the most consistent desk rejections worth knowing before submission.

The confirmatory trial of a guideline-recommended therapy. According to NEJM's author guidelines, the journal is interested in original research that is destined to change clinical practice; confirmatory studies demonstrating that guideline-recommended therapies perform as expected, without identifying an important exception or patient subgroup, are in our experience rejected at the desk. We see this pattern in manuscripts we review more frequently than any other NEJM-specific failure.

In our experience, many of the manuscripts we review targeting NEJM are confirmatory trials of established interventions where the primary finding aligns with current practice without meaningfully challenging it.

The observational analysis addressing a question answerable by a randomized trial. NEJM's statistical guidelines say causal language should not be used in observational studies where only associations can be estimated, and in our experience the journal expects the strongest available study design for any clinical question that can be randomized. Editors consistently reject observational cohort analyses on treatment effectiveness questions when a randomized controlled trial is feasible, regardless of the cohort size or multivariate adjustment approach used.

In our experience, many of the manuscripts we review for NEJM are large observational treatment-effect analyses where the confounding limitations undermine the practice-changing significance claim. In practice desk rejection tends to occur within two weeks when an editor identifies that a randomized design is both feasible and would provide stronger evidence.

The trial with hard outcomes buried in a surrogate-endpoint framing. NEJM's author guidelines ask for original research destined to change clinical practice; in our experience that means the journal prioritizes trials reporting mortality, hospitalization, or major adverse events as primary endpoints over imaging metrics or biomarker changes alone.

We see this in many of the manuscripts we review for NEJM, where trials measuring echocardiographic parameters, biomarker trajectories, or imaging findings are framed as primary evidence for clinical benefit without a hard outcome to support the claim. Editors consistently screen for this pattern during the initial editorial read.

The single-center study with limited generalizability.

NEJM says more than a million people from nearly every country read the journal each week, and in our experience it publishes research applicable to physicians across diverse healthcare systems globally. We see this in many of the manuscripts we review for NEJM, where the study population comes from a single referral center or a geographically limited health system with patient characteristics that restrict applicability across the diverse populations served by NEJM's global readership. In practice desk rejection tends to occur when an editor identifies that the findings cannot credibly inform broad clinical practice.

The statistical analysis that diverges from the pre-registered plan. According to NEJM's statistical reporting guidelines, a protocol and statistical analysis plan should be submitted with each manuscript, the primary-outcome analysis in a trial manuscript should match the prespecified analysis except in unusual circumstances, and analyses that do not conform to the protocol should be justified in the Methods section. Editors consistently reject manuscripts where the reported primary or secondary analyses appear to have been selected after the data were available.

In our experience, many of the manuscripts we review for NEJM have a discrepancy between the registered analysis plan and the reported analyses that is detectable from the methods section alone.

SciRev community data for New England Journal of Medicine offers an additional, unofficial benchmark for review timelines; NEJM itself publishes only the stage timings described above.

Before submitting to the New England Journal of Medicine, a NEJM manuscript fit check identifies whether the study design, clinical significance, and statistical rigor meet NEJM's editorial bar before you invest in the full submission process.

Ready to submit if:

• You can pass every item on this checklist without qualifying language

• An experienced colleague in your field has read the manuscript and agrees it's competitive

• The data package is complete - no pending experiments or analyses

• You have identified why this journal specifically (not just prestige) is the right venue

Not ready yet if:

• You skipped items on this checklist because you "plan to add them later"

• The methods section still has draft or incomplete protocol text

• Key figures are drafts rather than publication-quality

• You cannot articulate what distinguishes this paper from recent publications in this journal

For a manuscript-specific signal before you submit, run a free readiness scan.

Ready and well-matched are two different questions. See where NEJM lands among the venues that fit my abstract.